Literature DB >> 29256371

Plasma Concentration of Meloxicam in Pediatric Rats.

Kristina A Pugh1, Kyle J Reitnauer2, Robyn B Lee3, William L Wilkins4, John H McDonough5, M Ross Pennington6, Samantha R Litvin6.   

Abstract

In this study, we compared the plasma concentrations of meloxicam in pediatric rat pups (ages: 7, 14, 21, and 28 d) with those of young adult rats. Adult rats received 1.34 mg/kg SC meloxicam to determine the target peak plasma concentration (Cmax) for comparison with the pediatric animals. Pediatric rats received 1.34 mg/kg SC meloxicam, and in all age groups, Cmax met or exceeded that in adults (11.5 ±2.7 μg/mL). Plasma concentrations were similar between male and female pups within age groups, and peak plasma concentration was achieved more rapidly in rat pups than adults. The analgesic efficacy of this dose was not evaluated in this study.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29256371      PMCID: PMC5710155     

Source DB:  PubMed          Journal:  J Am Assoc Lab Anim Sci        ISSN: 1559-6109            Impact factor:   1.232


  25 in total

1.  Pharmacokinetic/pharmacodynamic modelling of NSAIDs in a model of reversible inflammation in the cat.

Authors:  Jerome M Giraudel; Armelle Diquelou; Valerie Laroute; Peter Lees; Pierre-Louis Toutain
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

2.  Pharmacokinetics of meloxicam in animals and the relevance to humans.

Authors:  U Busch; J Schmid; G Heinzel; H Schmaus; J Baierl; C Huber; W Roth
Journal:  Drug Metab Dispos       Date:  1998-06       Impact factor: 3.922

3.  Evaluation of pharmacological profile of meloxicam as an anti-inflammatory agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1.

Authors:  K Ogino; K Hatanaka; M Kawamura; M Katori; Y Harada
Journal:  Pharmacology       Date:  1997-07       Impact factor: 2.547

4.  Improved absorption of meloxicam via salt formation with ethanolamines.

Authors:  Hyo-Kyung Han; Hoo-Kyun Choi
Journal:  Eur J Pharm Biopharm       Date:  2006-07-15       Impact factor: 5.571

5.  The Measurement of Meloxicam and Meloxicam Metabolites in Rat Plasma Using a High-Performance Liquid Chromatography-Ultraviolet Spectrophotometry Method.

Authors:  Aoi Miyamoto; Takahiko Aoyama; Yoshiaki Matsumoto
Journal:  Chem Pharm Bull (Tokyo)       Date:  2016-12-01       Impact factor: 1.645

6.  Distribution of [14C]meloxicam in joints of rats with adjuvant arthritis.

Authors:  U Busch; G Engelhardt
Journal:  Drugs Exp Clin Res       Date:  1990

7.  Differential inhibition of cyclooxygenases-1 and -2 by meloxicam and its 4'-isomer.

Authors:  M Pairet; J van Ryn; H Schierok; A Mauz; G Trummlitz; G Engelhardt
Journal:  Inflamm Res       Date:  1998-06       Impact factor: 4.575

8.  Pharmacokinetics of meloxicam in koalas (Phascolarctos cinereus) after intravenous, subcutaneous and oral administration.

Authors:  B Kimble; L A Black; K M Li; P Valtchev; S Gilchrist; A Gillett; D P Higgins; M B Krockenberger; M Govendir
Journal:  J Vet Pharmacol Ther       Date:  2013-02-14       Impact factor: 1.786

9.  Pharmacokinetics of meloxicam in rabbits after single and repeat oral dosing.

Authors:  Patricia V Turner; H Cheng Chen; W Michael Taylor
Journal:  Comp Med       Date:  2006-02       Impact factor: 0.982

Review 10.  [Meloxicam (Mobic): a review of its pharmacological and clinical profile].

Authors:  Keiko Ogino; Kazushige Saito; Takeshi Osugi; Hisashi Satoh
Journal:  Nihon Yakurigaku Zasshi       Date:  2002-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.